Filing Details

Accession Number:
0001209191-19-044309
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-02 17:19:36
Reporting Period:
2019-07-18
Accepted Time:
2019-08-02 17:19:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1087294 Cumberland Pharmaceuticals Inc CPIX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1470015 R Gordon Bernard 2525 West End Ave.
Suite 950
Nashville TN 37203
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-07-18 500 $5.69 52,602 No 4 S Direct
Common Stock Disposition 2019-07-19 104 $5.61 52,498 No 4 S Direct
Common Stock Disposition 2019-07-22 200 $5.63 52,298 No 4 S Direct
Common Stock Disposition 2019-07-24 900 $5.84 51,398 No 4 S Direct
Common Stock Disposition 2019-07-25 500 $5.85 50,898 No 4 S Direct
Common Stock Disposition 2019-07-26 500 $5.83 50,398 No 4 S Direct
Common Stock Disposition 2019-07-29 424 $5.84 49,974 No 4 S Direct
Common Stock Disposition 2019-07-30 644 $5.81 49,330 No 4 S Direct
Common Stock Disposition 2019-07-31 1,100 $5.91 48,230 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.69 to $5.69, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.61 to $5.62, inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.64 to $5.62, inclusive.
  6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.89 to $5.76, inclusive.
  7. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.85, inclusive.
  8. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.80, inclusive.
  9. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.89 to $5.83, inclusive.
  10. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.83 to $5.80, inclusive.
  11. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.90, inclusive.